Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc reduced its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 5.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 714,849 shares of the biotechnology company's stock after selling 44,402 shares during the period. AEGON ASSET MANAGEMENT UK Plc owned approximately 0.93% of Veracyte worth $24,319,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its stake in shares of Veracyte by 2,331.6% during the second quarter. Blue Trust Inc. now owns 1,386 shares of the biotechnology company's stock valued at $31,000 after acquiring an additional 1,329 shares in the last quarter. CWM LLC grew its stake in shares of Veracyte by 168.3% during the second quarter. CWM LLC now owns 1,516 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 951 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Veracyte during the second quarter valued at about $58,000. Signature Resources Capital Management LLC acquired a new position in Veracyte in the second quarter worth about $83,000. Finally, nVerses Capital LLC acquired a new position in Veracyte in the second quarter worth about $85,000.

Insider Activity

In related news, insider John Leite sold 5,479 shares of the firm's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $29.78, for a total transaction of $163,164.62. Following the transaction, the insider now owns 76,174 shares in the company, valued at $2,268,461.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Evan/ Fa Jones sold 20,457 shares of the firm's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $32.20, for a total transaction of $658,715.40. Following the transaction, the director now owns 34,343 shares in the company, valued at $1,105,844.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Leite sold 5,479 shares of the firm's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $29.78, for a total transaction of $163,164.62. Following the transaction, the insider now owns 76,174 shares in the company, valued at $2,268,461.72. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,109 shares of company stock valued at $1,004,125. Insiders own 1.30% of the company's stock.

Veracyte Stock Performance

Shares of VCYT traded down $0.86 during mid-day trading on Friday, reaching $36.48. 902,733 shares of the company's stock traded hands, compared to its average volume of 763,608. The business's 50-day moving average price is $33.27 and its 200-day moving average price is $27.03. The stock has a market capitalization of $2.80 billion, a P/E ratio of -243.20 and a beta of 1.67. Veracyte, Inc. has a 12 month low of $18.61 and a 12 month high of $41.43.

Veracyte (NASDAQ:VCYT - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.17. The company had revenue of $115.86 million for the quarter, compared to analysts' expectations of $109.81 million. Veracyte had a positive return on equity of 3.07% and a negative net margin of 2.18%. The business's revenue for the quarter was up 28.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.03) earnings per share. Equities research analysts anticipate that Veracyte, Inc. will post 0.16 EPS for the current year.

Wall Street Analysts Forecast Growth

VCYT has been the subject of a number of research reports. The Goldman Sachs Group lifted their price target on Veracyte from $34.00 to $38.00 and gave the stock a "buy" rating in a research note on Thursday. Guggenheim began coverage on Veracyte in a research note on Thursday, October 10th. They issued a "buy" rating and a $40.00 price target for the company. Morgan Stanley raised their target price on shares of Veracyte from $21.00 to $26.00 and gave the stock an "underweight" rating in a report on Monday, August 12th. Leerink Partners raised their target price on shares of Veracyte from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Finally, UBS Group raised their target price on shares of Veracyte from $43.00 to $46.00 and gave the stock a "buy" rating in a report on Thursday. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Veracyte presently has an average rating of "Moderate Buy" and a consensus target price of $39.71.

About Veracyte

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.